203 related articles for article (PubMed ID: 17230548)
1. Methamphetamine blood concentrations in human abusers: application to pharmacokinetic modeling.
Melega WP; Cho AK; Harvey D; Laćan G
Synapse; 2007 Apr; 61(4):216-20. PubMed ID: 17230548
[TBL] [Abstract][Full Text] [Related]
2. Escalating dose pretreatment induces pharmacodynamic and not pharmacokinetic tolerance to a subsequent high-dose methamphetamine binge.
O'Neil ML; Kuczenski R; Segal DS; Cho AK; Lacan G; Melega WP
Synapse; 2006 Nov; 60(6):465-73. PubMed ID: 16897726
[TBL] [Abstract][Full Text] [Related]
3. Relevance of pharmacokinetic parameters in animal models of methamphetamine abuse.
Cho AK; Melega WP; Kuczenski R; Segal DS
Synapse; 2001 Feb; 39(2):161-6. PubMed ID: 11180503
[TBL] [Abstract][Full Text] [Related]
4. Sex- and dose-dependency in the pharmacokinetics and pharmacodynamics of (+)-methamphetamine and its metabolite (+)-amphetamine in rats.
Milesi-Hallé A; Hendrickson HP; Laurenzana EM; Gentry WB; Owens SM
Toxicol Appl Pharmacol; 2005 Dec; 209(3):203-13. PubMed ID: 15916788
[TBL] [Abstract][Full Text] [Related]
5. Spontaneous locomotor activity and pharmacokinetics of intravenous methamphetamine and its metabolite amphetamine in the rat.
Rivière GJ; Byrnes KA; Gentry WB; Owens SM
J Pharmacol Exp Ther; 1999 Dec; 291(3):1220-6. PubMed ID: 10565845
[TBL] [Abstract][Full Text] [Related]
6. [Pharmacokinetic behavioral changes of methamphetamine in methamphetamine-sensitized animal model].
Kitaichi K; Morishita Y; Hasegawa T
Nihon Shinkei Seishin Yakurigaku Zasshi; 2001 Nov; 21(5):133-44. PubMed ID: 11797416
[TBL] [Abstract][Full Text] [Related]
7. Methamphetamine and amphetamine pharmacokinetics in oral fluid and plasma after controlled oral methamphetamine administration to human volunteers.
Schepers RJ; Oyler JM; Joseph RE; Cone EJ; Moolchan ET; Huestis MA
Clin Chem; 2003 Jan; 49(1):121-32. PubMed ID: 12507968
[TBL] [Abstract][Full Text] [Related]
8. Long-term methamphetamine administration in the vervet monkey models aspects of a human exposure: brain neurotoxicity and behavioral profiles.
Melega WP; Jorgensen MJ; Laćan G; Way BM; Pham J; Morton G; Cho AK; Fairbanks LA
Neuropsychopharmacology; 2008 May; 33(6):1441-52. PubMed ID: 17625500
[TBL] [Abstract][Full Text] [Related]
9. Safety and efficiency of an anti-(+)-methamphetamine monoclonal antibody in the protection against cardiovascular and central nervous system effects of (+)-methamphetamine in rats.
Gentry WB; Laurenzana EM; Williams DK; West JR; Berg RJ; Terlea T; Owens SM
Int Immunopharmacol; 2006 Jun; 6(6):968-77. PubMed ID: 16644483
[TBL] [Abstract][Full Text] [Related]
10. Sex differences in methamphetamine pharmacokinetics in adult rats and its transfer to pups through the placental membrane and breast milk.
Rambousek L; Kacer P; Syslova K; Bumba J; Bubenikova-Valesova V; Slamberova R
Drug Alcohol Depend; 2014 Jun; 139():138-44. PubMed ID: 24726427
[TBL] [Abstract][Full Text] [Related]
11. Disposition of methamphetamine and its metabolite amphetamine in brain and other tissues in rats after intravenous administration.
Rivière GJ; Gentry WB; Owens SM
J Pharmacol Exp Ther; 2000 Mar; 292(3):1042-7. PubMed ID: 10688621
[TBL] [Abstract][Full Text] [Related]
12. (+)-Methamphetamine-induced spontaneous behavior in rats depends on route of (+)METH administration.
Gentry WB; Ghafoor AU; Wessinger WD; Laurenzana EM; Hendrickson HP; Owens SM
Pharmacol Biochem Behav; 2004 Dec; 79(4):751-60. PubMed ID: 15582684
[TBL] [Abstract][Full Text] [Related]
13. The effects of p-chloroamphetamine, methamphetamine and 3,4-methylenedioxymethamphetamine (ecstasy) on the gene expression of cytoskeletal proteins in the rat brain.
Putzke J; Spina MG; Büchler J; Kovar KA; Wolf G; Smalla KH
Addict Biol; 2007 Mar; 12(1):69-80. PubMed ID: 17407499
[TBL] [Abstract][Full Text] [Related]
14. Approaches to the development of medications for the treatment of methamphetamine dependence.
Vocci FJ; Appel NM
Addiction; 2007 Apr; 102 Suppl 1():96-106. PubMed ID: 17493058
[TBL] [Abstract][Full Text] [Related]
15. Methamphetamine-induced locomotor activity and behavioral sensitization: are dopamine d3 receptors involved?
Jones CD; Bartee JA; Leite-Browning ML; Blackshear MA
Cell Mol Biol (Noisy-le-grand); 2007 May; 53(4):15-22. PubMed ID: 17531156
[TBL] [Abstract][Full Text] [Related]
16. The role of organic cation transporter-3 in methamphetamine disposition and its behavioral response in rats.
Nakayama H; Kitaichi K; Ito Y; Hashimoto K; Takagi K; Yokoi T; Takagi K; Ozaki N; Yamamoto T; Hasegawa T
Brain Res; 2007 Dec; 1184():260-9. PubMed ID: 17988657
[TBL] [Abstract][Full Text] [Related]
17. Impairment related to blood amphetamine and/or methamphetamine concentrations in suspected drugged drivers.
Gustavsen I; Mørland J; Bramness JG
Accid Anal Prev; 2006 May; 38(3):490-5. PubMed ID: 16343411
[TBL] [Abstract][Full Text] [Related]
18. The pharmacokinetic properties of methamphetamine in rats with previous repeated exposure to methamphetamine: the differences between Long-Evans and Wistar rats.
Fujimoto Y; Kitaichi K; Nakayama H; Ito Y; Takagi K; Takagi K; Hasegawa T
Exp Anim; 2007 Apr; 56(2):119-29. PubMed ID: 17460357
[TBL] [Abstract][Full Text] [Related]
19. Neurotoxic-related changes in tyrosine hydroxylase, microglia, myelin, and the blood-brain barrier in the caudate-putamen from acute methamphetamine exposure.
Bowyer JF; Robinson B; Ali S; Schmued LC
Synapse; 2008 Mar; 62(3):193-204. PubMed ID: 18081184
[TBL] [Abstract][Full Text] [Related]
20. Ritanserin reverses repeated methamphetamine-induced behavioral and neurochemical sensitization in mice.
Ago Y; Nakamura S; Kajita N; Uda M; Hashimoto H; Baba A; Matsuda T
Synapse; 2007 Sep; 61(9):757-63. PubMed ID: 17568413
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
